The Cure of Disseminated Hodgkin's Disease: Prospects and Problems
Authors: ROLF A. STREULI
Journal: Annals of Internal Medicine (1980)

Editorials1 May 1980The Cure of Disseminated Hodgkin's Disease: Prospects and ProblemsROLF A. STREULI, M.D., JOHN E. ULTMANN, M.D.ROLF A. STREULI, M.D.Search for more papers by this author, JOHN E. ULTMANN, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-92-5-693 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptSixteen years ago the first patients with advanced Hodgkin's disease were treated with the four-drug chemotherapy regimen MOPP (mechlorethamine, vincristine, procarbazine, and prednisone) at the National Cancer Institute of the National Institutes of Health. In this month's issue, DeVita and coworkers (1) give account of the long-term follow-up of the patients treated with this combination. The introduction of MOPP into the armamentarium against Hodgkin's disease was a breakthrough that changed the prognosis from an inevitably fatal outcome for advanced stages of this disease to good chances of cure in many cases.What led to the selection of the four-drug regimen...References1. DEVITA V, SIMON R, and HUBBARD S. Curability of advanced Hodgkin's disease with chemotherapy: long-term follow-up of MOPP-treated patients at the National Cancer Institute. Ann Intern Med. 1980;92:587-95. LinkGoogle Scholar2. FREI E, KARON M, and LEVIN R. The effectiveness of combinations of antileukemic agents in inducing and maintaining remission in children with acute leukemia. Blood. 1965;26:642-56. CrossrefMedlineGoogle Scholar3. CARBONE P, SPUR C, SCHNEIDERMAN M, SCOTTO J, HOLLAND J, and SHNIDER B. Management of patients with malignant lymphoma: a comparative study with cyclophosphamide and vinca aklaloids. Cancer Res. 1968;28:811-22. MedlineGoogle Scholar4. DEVITA V, LEWIS B, ROZENCWEIG M, and MUGGIA F. The chemotherapy of Hodgkin's disease: past experience and future directions. Cancer. 1978;42:979-90. CrossrefMedlineGoogle Scholar5. LACHER M and DURANT J. Combined vinblastine and chlorambucil therapy of Hodgkin's disease. Ann Intern Med. 1965;62:468-76. LinkGoogle Scholar6. SKIPPER H, SCHABEL F, and WILCOX W. Experimental evaluation of potential anticancer agents: III. On the criteria and kinetics associated with "curability" of experimental leukemia. Cancer Chemother Rep. 1964;35:1-111. MedlineGoogle Scholar7. MOXLEY J, DEVITA V, BRACE K, and FREI E. Intensive combination chemotherapy and x-irradiation in Hodgkin's disease. Cancer Res. 1967;27:1258-63. MedlineGoogle Scholar8. COLEMAN C, WILLIAMS C, FLINT A, GLATSTEIN E, ROSENBERG S, and KAPLAN H. Hematologic neoplasia in patients treated for Hodgkin's disease. N Engl J Med. 1977;297:1249-52. CrossrefMedlineGoogle Scholar9. KRIKORIAN J, BURKE J, ROSENBERG S, and KAPLAN H. Occurrence of non-Hodgkin's lymphoma after therapy for Hodgkin's disease. N Engl J Med. 1979;300:452-8. CrossrefMedlineGoogle Scholar10. ROWLEY J, GOLOMB H, and VARDIMAN J. Nonrandom chromosomal abnormalities in acute nonlymphocytic leukemia in patients treated for Hodgkin's disease and non-Hodgkin's lymphomas. Blood. 1977;50:759-70. Google Scholar11. MITELMAN F, BRANDT L, and NILSSON P. Relation among occupational exposure to potential mutagenic/carcinogenic agents, clinical findings, and bone marrow chromosomes in acute nonlymphocytic leukemia. Blood. 1978;52:1229-37. CrossrefMedlineGoogle Scholar12. CHAPMAN R, SUTCLIFFE S, REES L, EDWARDS C, and MALPAS J. Cyclical combination chemotherapy and gonadal function: retrospective study in males. Lancet. 1979;1:285-9. CrossrefMedlineGoogle Scholar13. SHERINS R, WINOKUR S, DEVITA V, and VAITUKAITIS J. Surprisingly high risk of functional castration in women receiving chemotherapy for lymphoma. Clin Res. 1975;23:343 A. Abstract. Google Scholar14. FISHER R, DEVITA V, and BOSTICK F. Persistent immunologic abnormalities in long-term survivors of advanced Hodgkin's disease. Ann Intern Med. 1980;92:595-9. LinkGoogle Scholar15. FISHER R, DEVITA V, HUBBARD S, SIMON R, and YOUNG R. Prolonged disease-free survival in Hodgkin's disease with MOPP reinduction after first relapse. Ann Intern Med. 1979;90:761-3. LinkGoogle Scholar16. BONADONNA G, ZUCALI R, MONFARDINI S, DELENA M, and USLENGHI C. Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer. 1975;36:252-9. CrossrefMedlineGoogle Scholar17. CASE D, YOUNG C, and LEE B. Combination chemotherapy of MOPP-resistant Hodgkin's disease with adriamycin, bleomycin, decarbazine and vinblastine (ABVD). Cancer. 1977;39:1382-6. CrossrefMedlineGoogle Scholar18. BONADONNA G, ZUCALI R, DELENA M, and VALAGUSSA P. Combined chemotherapy (MOPP or ABVD)-radiotherapy approach in advanced Hodgkin's disease. Cancer Treat Rep. 1977;61:769-77. MedlineGoogle Scholar19. VINCIGUERRA V, COLEMAN M, JAROWSKI C, DEGNAN T, and SILVER R. A new combination chemotherapy for resistant Hodgkin's disease. JAMA. 1977;237:33-5. CrossrefMedlineGoogle Scholar20. PORZIG K and ROBERTSON A. Treatment of advanced Hodgkin's disease (HD) with B-CAVE following MOPP failure. Proc Am Soc Clin Oncol. 1977;18:342. Abstract. Google Scholar21. LOKICH J, FREI E, JAFFE N, and TULLIS J. New multiple-agent chemotherapy (B-DOPA) for advanced Hodgkin's disease. Cancer. 1976;38:667-71. CrossrefMedlineGoogle Scholar22. SMYTH J, YOUNG R, and YOUNG D. In-vivo toxicity to lymphoid tissue by 2′-deoxycoformycin. Cancer Chemother Pharmacol. 1978;1:49-51. CrossrefMedlineGoogle Scholar23. PROSNITZ L, FARBER L, FISCHER J, BERTINO J, and FISCHER D. Long term remissions with combined modality therapy for advanced Hodgkin's disease. Cancer. 1976;37:2826-33. CrossrefMedlineGoogle Scholar24. VALAGUSSA P, KENDA R, and FOSSATI BELLANI F. Incidence of second malignancies in Hodgkin's disease (HD) after various forms of treatment. Proc Am Soc Clin Oncol. 1979;20:360. Abstract. Google Scholar25. DEVITA V, CANELLOS G, HUBBARD S, CHABNER B, and YOUNG R. Chemotherapy of Hodgkin's disease (HD) with MOPP: A 10 yr. progress report. Proc Am Soc Clin Oncol. 1976;17:269. Abstract. Google Scholar26. COLTMAN C, FREI E, and MOON T. MOPP maintenance (MM) vs unmaintained remission (UMR) for MOPP induced complete remission (CR) of advanced Hodgkin's disease. Proc Am Soc Clin Oncol. 1976;17:289. Abstract. Google Scholar27. ROSENBERG S, KAPLAN H, GLATSTEIN E, and PORTLOCK C. Combined modality therapy of Hodgkin's disease: a report on the Stanford trials. Cancer. 1978;42:991-1000. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: ROLF A. STREULI, M.D.; JOHN E. ULTMANN, M.D.Affiliations: Department of Medicine and the Cancer Research Center The University of Chicago Chicago, Illinois PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 May 1980Volume 92, Issue 5Page: 693-695KeywordsCancer chemotherapyChemotherapyHodgkin lymphomaMechlorethamineProcarbazine ePublished: 1 December 2008 Issue Published: 1 May 1980 PDF downloadLoading ...